

HOSPITAL SULTAN ABDUL AZIZ SHAH UNIVERSITI PUTRA MALAYSIA Kod Dokumen: HSAAS/MEDIC/BR235

CYTARABINE (ARA-C) FOR ACUTE MYELOID LEUKEMIA IN OLDER PATIENT FORM

NAME :		RN : IC :		
HEIGHT (CM) :	WEIGHT (KG) :	BSA (m ₂) :	WARD:	
DIAGNOSIS: Acute Myeloid Leukemia		Discipline:	Remarks:	

CYTARABINE PROTOCOL SUMMARY

Low dose Cytarabine (Ara-C)	Subcutaneous injection	10 consecutive days, every 4-6		
	20mg OD/BD	weeks		

References : Mediterranean Journal of Hematology and Infectious Disease

- 1. Obtain patient's formal consent for R. Counsel accordingly.
- 2. Review FBC, RP, LFT, Coagulation profile, HIV, Hep C, Hep BsAg and B core antigen before treatment.
- 3. Ensure to double check the indications and dose with Consultant Haematologist, Medical Officer, Clinical Nurse Specialist and Pharmacist before indenting chemotherapy.
- 4. The hard copy of this protocol should be kept in patient's hospital chemotherapy file and after completion to be inserted in their major file in the medical record office.
- 5. Blood product transfusion systemically administered when Haemoglobin <80 g/l, platelet < 20x109

Dose modification:	YES / NO	If YES , state drug, new dose, and reason:			
Drug:		Dose:	Reason:		



HOSPITAL SULTAN ABDUL AZIZ SHAH UNIVERSITI PUTRA MALAYSIA Kod Dokumen: HSAAS/MEDIC/BR235

CYTARABINE (ARA-C) FOR ACUTE MYELOID LEUKEMIA IN OLDER PATIENT FORM

PROTOCOL DECISION

REGIME	1 st cycle	2 ND cycle	3 RD cycle	4 [™] cycle
Dosage of Cytarabine				

Indented by:	Signature:	Date:
Verified by:	Signature:	Date:

NAME:	RN:

Mediterranean Journal of Hematology and Infectious Disease Review

Low dose cytarabine was suggested for patient considered 'unfit' for intensive chemotherapy. It is relatively well tolerated and can be given in outpatient setting



HOSPITAL SULTAN ABDUL AZIZ SHAH UNIVERSITI PUTRA MALAYSIA Kod Dokumen: HSAAS/MEDIC/BR235

CYTARABINE (ARA-C) FOR ACUTE MYELOID LEUKEMIA IN OLDER PATIENT FORM

CYTARABINE CALENDAR

TIME	SIGNATURE	TIME	SIGNATURE	TIME	SIGNATURE